[HTML][HTML] Tofacitinib or adalimumab versus placebo in rheumatoid arthritis
…, S Forejtova, SH Zwillich, D Gruben… - … England Journal of …, 2012 - Mass Medical Soc
Background Tofacitinib (CP-690,550) is a novel oral Janus kinase inhibitor that is being
investigated for the treatment of rheumatoid arthritis. Methods In this 12-month, phase 3 trial, 717 …
investigated for the treatment of rheumatoid arthritis. Methods In this 12-month, phase 3 trial, 717 …
[HTML][HTML] Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis
…, CA Connell, JD Bradley, D Gruben… - … England Journal of …, 2012 - Mass Medical Soc
Background Tofacitinib (CP-690,550) is a novel oral Janus kinase inhibitor that is being
investigated as a targeted immunomodulator and disease-modifying therapy for rheumatoid …
investigated as a targeted immunomodulator and disease-modifying therapy for rheumatoid …
[HTML][HTML] Tofacitinib versus methotrexate in rheumatoid arthritis
…, B Wilkinson, JD Bradley, D Gruben… - … England Journal of …, 2014 - Mass Medical Soc
Background Methotrexate is the most frequently used first-line antirheumatic drug. We report
the findings of a phase 3 study of monotherapy with tofacitinib, an oral Janus kinase inhibitor…
the findings of a phase 3 study of monotherapy with tofacitinib, an oral Janus kinase inhibitor…
Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors …
…, J Wollenhaupt, C Zerbini, B Benda, D Gruben… - The Lancet, 2013 - thelancet.com
Background Rheumatoid arthritis is a heterogeneous chronic disease, and no therapeutic
agent has been identified which is universally and persistently effective in all patients. We …
agent has been identified which is universally and persistently effective in all patients. We …
The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double‐blind, placebo‐controlled phase IIa trial of three dosage levels …
…, JH Coombs, MP Fletcher, D Gruben… - … : Official Journal of …, 2009 - Wiley Online Library
Objective To determine the efficacy, safety, and tolerability of 3 different dosages of CP‐690,550,
a potent, orally active JAK inhibitor, in patients with active rheumatoid arthritis (RA) in …
a potent, orally active JAK inhibitor, in patients with active rheumatoid arthritis (RA) in …
Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve‐month data from a twenty‐four–month phase III randomized radiographic …
…, D Tegzová, BT Wyman, D Gruben… - Arthritis & …, 2013 - Wiley Online Library
Objective The purpose of this 24‐month phase III study was to examine structural preservation
with tofacitinib in patients with rheumatoid arthritis (RA) with an inadequate response to …
with tofacitinib in patients with rheumatoid arthritis (RA) with an inadequate response to …
Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial
…, E Martin-Mola, JD Isaacs, D Gruben… - Annals of internal …, 2013 - acpjournals.org
Chinese translation Background: Many patients with rheumatoid arthritis (RA) do not
achieve adequate and safe responses with disease-modifying antirheumatic drugs (DMARDs). …
achieve adequate and safe responses with disease-modifying antirheumatic drugs (DMARDs). …
Phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis …
…, KS Kanik, S Sadis, CA Connell, D Gruben… - Arthritis & …, 2012 - Wiley Online Library
Objective To compare the efficacy, safety, and tolerability of 5 doses of oral tofacitinib (CP‐690,550)
or adalimumab monotherapy with placebo for the treatment of active rheumatoid …
or adalimumab monotherapy with placebo for the treatment of active rheumatoid …
A phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) versus placebo in combination with background methotrexate in patients with active …
…, JL French, J Gomez‐Reino, D Gruben… - Arthritis & …, 2012 - Wiley Online Library
Objective To compare the efficacy, safety, and tolerability of 6 dosages of oral tofacitinib (CP‐690,550)
with placebo for the treatment of active rheumatoid arthritis (RA) in patients …
with placebo for the treatment of active rheumatoid arthritis (RA) in patients …
Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies
…, K Soma, CI Nduaka, B Benda, D Gruben… - The Journal of …, 2014 - jrheum.org
Objective. To describe the longterm safety and efficacy profile of tofacitinib in patients with
moderate to severe active rheumatoid arthritis (RA). Methods. Data were pooled from 2 open-…
moderate to severe active rheumatoid arthritis (RA). Methods. Data were pooled from 2 open-…